Send the following on WhatsApp
Continue to ChatSosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease https://insideout.vn/sosei-heptares-doses-first-subject-in-phase-1-trial-with-htl0033744-an-ep4-agonist-for-inflammatory-bowel-disease/